Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation

Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of diseaseSAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation. The collaboration will combine leading Illumin ...